Evaluation of the role of secretory sphingomyelinase and bioactive sphingolipids as biomarkers in hemophagocytic lymphohistiocytosis

American Journal of Hematology

Volumn 88, Issue 11, 2013, Pages

  Jenkins, Russell W ^a   Clarke, Christopher J ^b   Lucas, John Thomas ^c   Shabbir, Munira ^d,e   Wu, Bill X ^d   Simbari, Fabio ^f   Mueller, Joan ^d   Hannun, Yusuf A ^b   Lazarchick, John ^d   Shirai, Keisuke ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

^f INSTITUTE OF ADVANCED CHEMISTRY OF CATALONIA IQAC CSIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CERAMIDE; FERRITIN; FIBRINOGEN; INTERLEUKIN 2 RECEPTOR ALPHA; SPHINGOLIPID; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOSINE 1 PHOSPHATE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS INFECTION; ERYTHROPHAGOCYTOSIS; FELTY SYNDROME; FEMALE; GENETIC SCREENING; HEMOPHAGOCYTIC SYNDROME; HEPATOMEGALY; HEPATOSPLENOMEGALY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; LARGE CELL LYMPHOMA; LYMPHADENOPATHY; MALE; MOLECULAR DYNAMICS; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN SECRETION; PROTHROMBIN TIME; SARCOIDOSIS; SPLENOMEGALY; SUBACUTE ENDOCARDITIS; T CELL LYMPHOMA; THROMBOCYTE COUNT; UPREGULATION;

EID: 84886289791     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23535     Document Type: Article

References (48)

1. Filipovich AH. Hemophagocytic lymphohistiocytosis (HLH) and related disorders. Hematology/The Education Program of the American Society of Hematology. Am Soc Hematol Educ Prog 2009:127-131.
2. Gupta S, Weitzman S. Primary and secondary hemophagocytic lymphohistiocytosis: Clinical features, pathogenesis and therapy. Expert Rev Clin Immunol 2010;6:137-154.
3. Filipovich AH. The expanding spectrum of hemophagocytic lymphohistiocytosis. Curr Opin Allergy Clin Immunol 2011;11:512-516.
4. Henter JI, Elinder G, Soder O, et al. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scand 1991;80:428-435.
5. Clementi R, Emmi L, Maccario R, et al. Adult onset and atypical presentation of hemophagocytic lymphohistiocytosis in siblings carrying PRF1 mutations. Blood 2002;100:2266-2267.
6. Nagafuji K, Nonami A, Kumano T, et al. Perforin gene mutations in adult-onset hemophagocytic lymphohistiocytosis. Haematologica 2007;92:978-981.
7. Jordan MB, Allen CE, Weitzman S, et al. How I treat hemophagocytic lymphohistiocytosis. Blood 2011;118:4041-4052.
8. Perez N, Virelizier JL, Arenzana-Seisdedos F, et al. Impaired natural killer activity in lymphohistiocytosis syndrome. J Pediatr 1984;104:569-573.
9. Raschke RA, Garcia-Orr R. Hemophagocytic lymphohistiocytosis: A potentially underrecognized association with systemic inflammatory response syndrome, severe sepsis, and septic shock in adults. Chest 2011;140:933-938.
10. Janka GE. Familial hemophagocytic lymphohistiocytosis. Eur J Pediatr 1983;140:221-230.
11. Trottestam H, Horne A, Arico M, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: Long-term results of the HLH-94 treatment protocol. Blood 2011;118:4577-4584.
12. Nishi M, Nishimura R, Suzuki N, et al. Reduced-intensity conditioning in unrelated donor cord blood transplantation for familial hemophagocytic lymphohistiocytosis. Am J Hematol 2012;87:637-639.
13. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: Lessons from sphingolipids. Nat Rev Mol Cell Biol 2008;9:139-150.
14. Strub GM, Maceyka M, Hait NC, et al. Extracellular and intracellular actions of sphingosine-1-phosphate. Adv Exp Med Biol 2010;688:141-155.
15. Hammad SM. Blood sphingolipids in homeostasis and pathobiology. Adv Exp Med Biol 2011;721:57-66.
16. Hojjati MR, Li Z, Zhou H, et al. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J Biol Chem 2005;280:10284-10289.
17. Sattler KJ, Elbasan S, Keul P, et al. Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. Basic Res Cardiol 2010;105:821-832.
18. Drobnik W, Liebisch G, Audebert FX, et al. Plasma ceramide and lysophosphatidylcholine inversely correlate with mortality in sepsis patients. J Lipid Res 2003;44:754-761.
19. Park TS, Panek RL, Rekhter MD, et al. Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice. Atherosclerosis 2006;189:264-272.
20. Milhas D, Clarke CJ, Hannun YA. Sphingomyelin metabolism at the plasma membrane: Implications for bioactive sphingolipids. FEBS Lett 2010;584:1887-1894.
21. Schuchman EH. The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease. Int J Clin Pharmacol Ther 2009;47 Suppl 1:S48-S57.
22. Marathe S, Schissel SL, Yellin MJ, et al. Human vascular endothelial cells are a rich and regulatable source of secretory sphingomyelinase. Implications for early atherogenesis and ceramide-mediated cell signaling. J Biol Chem 1998;273:4081-4088.
23. Jenkins RW, Canals D, Idkowiak-Baldys J, et al. Regulated secretion of acid sphingomyelinase: Implications for selectivity of ceramide formation. J Biol Chem 2010;285:35706-35718.
24. Wong ML, Xie B, Beatini N, et al. Acute systemic inflammation up-regulates secretory sphingomyelinase in vivo: A possible link between inflammatory cytokines and atherogenesis. Proc Natl Acad Sci USA 2000;97:8681-8686.
25. Claus RA, Bunck AC, Bockmeyer CL, et al. Role of increased sphingomyelinase activity in apoptosis and organ failure of patients with severe sepsis. FASEB J 2005;19:1719-1721.
26. Doehner W, Bunck AC, Rauchhaus M, et al. Secretory sphingomyelinase is upregulated in chronic heart failure: A second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. Eur Heart J 2007;28:821-828.
27. 2+-dependent sphingomyelinase activity in the serum of patients with type 2 diabetes is elevated. Horm Metab Res 2003;35:506-507.
28. Takahashi T, Abe T, Sato T, et al. Elevated sphingomyelinase and hypercytokinemia in hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol 2002;24:401-404.
29. Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124-131.
30. Bielawski J, Szulc ZM, Hannun YA, et al. Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods 2006;39:82-91.
31. Liebisch G, Vizcaino JA, Kofeler H, et al. Shorthand notation for lipid structures derived from mass spectrometry. J Lipid Res 2013;54:1523-1530.
32. Hannun YA, Obeid LM. Many ceramides. J Biol Chem 2011;286:27855-27862.
33. Nixon GF. Sphingolipids in inflammation: Pathological implications and potential therapeutic targets. Br J Pharmacol 2009;158:982-993.
34. Jenkins RW, Canals D, Hannun YA. Roles and regulation of secretory and lysosomal acid sphingomyelinase. Cell Signal 2009;21:836-846.
35. Quintern LE, Sandhoff K. Human acid sphingomyelinase from human urine. Methods Enzymol 1991;197:536-540.
36. He X, Okino N, Dhami R, et al. Purification and characterization of recombinant, human acid ceramidase. Catalytic reactions and interactions with acid sphingomyelinase. J Biol Chem 2003;278:32978-32986.
37. Jenkins RW, Clarke CJ, Canals D, et al. Regulation of CC ligand 5/RANTES by acid sphingomyelinase and acid ceramidase. J Biol Chem 2011;286:13292-13303.
38. Golan K, Vagima Y, Ludin A, et al. S1P promotes murine progenitor cell egress and mobilization via S1P1 mediated ROS signaling and SDF-1 release. Blood 2012;119:2478-2488.
39. Herz J, Pardo J, Kashkar H, et al. Acid sphingomyelinase is a key regulator of cytotoxic granule secretion by primary T lymphocytes. Nat Immunol 2009;10:761-768.
40. Bianco F, Perrotta C, Novellino L, et al. Acid sphingomyelinase activity triggers microparticle release from glial cells. EMBO J 2009;28:1043-1054.
41. Tischner D, Theiss J, Karabinskaya A, et al. Acid sphingomyelinase is required for protection of effector memory T cells against glucocorticoid-induced cell death. J Immunol 2011;187:4509-4516.
42. Jenkins RW, Clarke CJ, Canals D, et al. Regulation of CC ligand 5/RANTES by acid sphingomyelinase and acid ceramidase. J Biol Chem 2011;286:13292-13303.
43. Levy JA. The unexpected pleiotropic activities of RANTES. J Immunol 2009;182:3945-3946.
44. Pachlopnik Schmid J, Ho CH, Chretien F, et al. Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice. EMBO Mol Med 2009;1:112-124.
45. Pachlopnik Schmid J, Ho CH, Diana J, et al. A Griscelli syndrome type 2 murine model of hemophagocytic lymphohistiocytosis (HLH). Eur J Immunol 2008;38:3219-3225.
46. Kameyoshi Y, Dorschner A, Mallet AI, et al. Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med 1992;176:587-592.
47. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-1140.
48. Canals D, Perry DM, Jenkins RW, et al. Drug targeting of sphingolipid metabolism: Sphingomyelinases and ceramidases. Br J Pharmacol 2011;163:694-712.